UnknownNot Applicable

Platelet Transfusion in Acute Intracerebral Hemorrhage

Finland100 participantsStarted 2009-01

Plain-language summary

* To prove whether use of antiplatelet agents results into a rapid enlargement of hematoma after onset of acute intracerebral hemorrhage. * To prove the efficacy and safety of platelet transfusion for prevention of hematoma growth in patients who were stricken by acute intracerebral hemorrhage while being on antiplatelet medication.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * being on either aspirin or clopidogrel or a combination of aspirin and dipyridamole * acute primary ICH * \> 17 years * admitted within 6 h after onset of ICH * ICH score \< 4 Exclusion Criteria: * other type of ICH than acute primary intracerebral hemorrhage * patients who need neurosurgery * life expectancy less than 3 months due to comorbid disorders * confirmed malignant disease (cancer) * confirmed acute myocardial infarction * hepatitis and/liver cirrhosis * renal failure * infectious disease (HIV, endocarditis etc.) * current or previous hematologic disease * women of childbearing age if pregnant * participation in another study within the preceding 30 days

What they're measuring

Hematoma growth within 24 h measured as increase in hematoma volume observed by head CT

Timeframe: 24 hours

Trial details

NCT IDNCT00699621

SponsorUniversity of Oulu

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-07

Contact for this trial

Matti E Hillbom, MD, PhD

358-8-315-4518 matti.hillbom@oulu.fi

View on ClinicalTrials.gov More Intracerebral Hemorrhage trials